JPL Wealth Management’s INmune Bio INMB Stock Holding History

JPL Wealth Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10	Buy	+6	New	+$8	﹤0.01%	1842

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JPL Wealth Management's INMB Position: Q2 2026 in Review

JPL Wealth Management opened a new position in INmune Bio (INMB) in Q2 2026: 6 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #1842 among its holdings.

83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

JPL Wealth Management held 6 shares of INmune Bio worth $10 as of Q2 2026.
INmune Bio was a new JPL Wealth Management position in Q2 2026.
INmune Bio made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #1842 holding.
83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.